In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Translate Bio Inc.

https://translate.bio

Latest From Translate Bio Inc.

Finance Watch: Two New IPOs – IGM In the US, Henlius In Hong Kong – Gross Nearly $600m

Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.

Financing Business Strategies

Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory

Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.

Financing Business Strategies

Dyne Launches With $50m For Antibody Conjugates That Deliver Oligonucleotides To Muscles

The start-up incubated by Atlas Venture is focused on the delivery of nucleic acids and other molecules to skeletal, cardiac and smooth muscles. The Series A round will allow Dyne to take its lead program for myotonic dystrophy type 1 (DM1) into the clinic.

Financing StartUps and SMEs

Early Stage Candidates Carving Out New Routes In Cystic Fibrosis

Scrip spoke to two companies from a fresh wave of innovators that are approaching drug development for cystic fibrosis from a new angle.

Respiratory Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • lncRNA Inc.
  • RaNA Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Translate Bio Inc.
  • Senior Management
  • Ronald C Renaud Jr., CEO
    John Schroer, CFO
    Michael Heartlein, PhD, CTO
    Brian Fenton, CBO
    Ann Barbier, MD, PhD, CMO
    Frank DeRosa, PhD, SVP, R&D
    Richard Wooster, BSc, PhD, CSO
  • Contact Info
  • Translate Bio Inc.
    Phone: (617) 945-7361
    29 Hartwell Ave.
    Lexington, MA 02421
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register